The “Invisible Epidemic”: Adapting Inpatient Detoxification Strategies for Geriatric Patients
Nathalie Gomez Abreu,Lea Marin,Amy Swift,John Jung
DOI: https://doi.org/10.1016/j.jagp.2024.01.141
2024-04-01
Abstract:Introduction The geriatric population is growing, and by 2030, 20% of the US population will be adults age 65 years and older. As this demographic increases, so does their incidence of alcohol and drug use. For example, in 2002, only 2.5% of adults aged 60-64 reported past month illicit drug use. In 2021, this number increased to 11%.2 Furthermore, the 2021 National Survey on Drug Use and Health reported that 4.7% and 7.6% of adults age 50 years or older reported Drug Use Disorders and Alcohol Use Disorders, respectively. However, despite these rising numbers, there is limited data identifying the unique diagnostic presentations of Substance Use Disorders (SUD) in older adults, as well as age-specific treatment guidelines for this population. The misuse of alcohol and benzodiazepines in the geriatric population is particularly concerning given that older adults are at greater risk for negative physical and mental health outcomes associated with substance use. Specifically, older adults may experience increased sensitivity to alcohol and sedatives due to altered metabolism (decreased renal and hepatic clearance, decreased muscle mass and total body water, and increased central nervous system sensitivity to substances) as well as higher rates of drug interactions given the frequency of polypharmacy in this population. Ultimately, this increases the risk of morbidity and mortality from falls, motor vehicle accidents, mood and cognitive disorders, sleep disorders, worsening of existing health diagnoses (e.g., cancer, diabetes, hypertension, congestive heart failure) and an increased rate of substance-related diseases (e.g., cirrhosis and pancreatitis). Furthermore, inpatient detoxification poses unique challenges in this population given age-related physiologic changes, increased likelihood of comorbid health conditions, increased risk of polypharmacy, personality construct and values, social network availability, life transition and psychosocial stressors, as well as substance availability and quality.2,5Despite the growing incidence of these disorders and their association with significant morbidity and mortality, geriatric alcohol and benzodiazepine misuse is still part of an “Invisible Epidemic”. This study seeks to shine light on the unique characteristics of SUD treatment in this population by describing the demographics and treatment course of 288 patients admitted to the Mount Sinai Beth Israel's detoxification unit from March-July 2023. Methods We conducted an observational, cross-sectional, quality improvement study on the treatment course of 288 patients aged 18-76 years admitted to Mount Sinai Beth Israel's inpatient detoxification unit in New York City from 03/01/2023-6/20/2023. De-identified patient information was gathered using Mount Sinai Hospital's electronic medical record navigator tool in Epic. We collected information on patient demographics (age, gender, race/ethnicity), as well as details on the detoxification medications administered, length of stay, and readmission rates. Results Preliminary Baseline Characteristics: Older adults (>50 years) encompassed 58% (n=142) of admissions to the detoxification unit. The majority of patients were male (87%, n=211). Preliminary Treatment Modality: Detoxification drug of choice varied by age. In individuals >50 years, lorazepam was the predominant detoxification agent (70%, n=100), followed by diazepam (22%, n=31), and clonazepam (8%, n=11). In contrast, younger patients (<50) were more frequently detoxified with diazepam (71%, n=72), with fewer treated with lorazepam (19%, n=19) and clonazepam (10%, n=10). Conclusions This study draws attention to the rising burden of substance use and SUDs, specifically alcohol and benzodiazepine use disorders among older adults. Our findings that the majority of admitted patients were >50 years old, underscores the urgency for specialized, age-sensitive and patient-centered healthcare responses. Furthermore, our preference for Lorazepam, a medication that is not filtered through the liver, may be a good choice to minimize risks in older adults. This study emphasizes that to effectively address the increasing prevalence of substance use and SUDs in older adults, an integrative approach combining medical and psychosocial strategies is paramount.
psychiatry,geriatrics & gerontology,gerontology